It has several defence mechanisms to evade oxidative and nitrosative agents released by phagocytic host cells during infection
The problem was its short half-life natural GLP-1 is rapidly degraded by the enzyme DPP-4, making it unsuitable for therapy in its native form
Researchers with existing cardiovascular disease, elevated baseline TMAO levels, or significant cardiovascular risk factors should discuss this specific concern with their healthcare provider before starting a levocarnitine-containing compound
Kell DB, Laubscher GJ, Pretorius E
A 2025 study found that people taking GLP-1 medications performed significantly worse on taste tests across all five basic tastes, sweet, salty, sour, bitter and umami, while their sense of smell remained largely unchanged